Navigation Links
Neurocrine Biosciences Announces the Start of Second Phase III Study of Elagolix in Endometriosis
Date:8/29/2013

p>Elagolix inhibits gonadotropin releasing hormone (GnRH) receptors in the pituitary gland and ultimately reduces circulating sex hormone levels. To date, elagolix has been studied in over 20 clinical trials totaling more than 1,000 subjects. At the time of expected NDA filing for endometriosis, elagolix will have been studied in over 25 clinical trials and in excess of 3,000 subjects. A Phase IIb trial of elagolix for the treatment of uterine fibroids is also ongoing.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc. is a clinical stage drug discovery company primarily focused on neurological and endocrine based diseases and disorders. The Company discovers and develops innovative pharmaceuticals, in diseases with high unmet medical needs or where the existing drug classes are inadequate, through a disciplined yet entrepreneurial process. Utilizing a portfolio approach to drug discovery, Neurocrine has multiple small molecule drug candidates at various stages of pharmaceutical development. Neurocrine's two lead late stage clinical programs are elagolix, a GnRH antagonist for women's health that is partnered with AbbVie Inc., and a wholly owned VMAT2 inhibitor for the treatment of movement disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.

In addition to historical facts, this press release may contain forward-looking statements that involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with Neurocrine's business and finances in general, as well as risks and uncertainties associated with the Company's GnRH program and Company overall. Specifically, the risks and uncertainties the Company faces with respect to the Company's GnRH program include,
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Neurocrine Biosciences to Present at the Jefferies 2013 Global Healthcare Conference
2. Neurocrine Biosciences to Present At The Deutsche Bank 38th Annual dbAccess Health Care Conference
3. Neurocrine Biosciences Reports First Quarter 2013 Results
4. Neurocrine Biosciences to Present at the Needham 12th Annual Healthcare Conference
5. Neurocrine Biosciences Announces the Start of Phase IIb Study of Elagolix in Uterine Fibroids
6. Neurocrine Biosciences To Present At The 25th Annual Roth Conference
7. Neurocrine Biosciences To Present At The Cowen And Company 33rd Annual Health Care Conference
8. Neurocrine Biosciences To Present At The Leerink Swann Global Healthcare Conference 2013
9. Neurocrine Biosciences Announces Conference Call And Webcast To Present Fourth Quarter And Year-End 2012 Financial Results
10. Neurocrine Biosciences Announces Additional European And United States Patents Issued On Proprietary VMAT2 Inhibitor
11. Neurocrine Biosciences To Present At Deutsche Banks 2012 dbAccess BioFEST
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... 2014 The western European automated endoscope ... largely a replacement market with fewer new installations ... and partnerships are redefining competitive landscape in western ... provides details about revenue forecasts, unit shipments, market ... the country. The changing landscape makes it important ...
(Date:9/22/2014)... , September 22, 2014 ... http://www.researchandmarkets.com/research/8ndtrc/freeze_drying_ ) has announced the addition of ... (Lab, Pilot, & Industrial) Market - Forecast ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,The global freeze ... in 2014 and is expected to reach ...
(Date:9/22/2014)... September 22, 2014 Final ... 25   The second edition of the ... excited to announce the final nominations for the 2014 ... on the evening of September 25 at The Taj Mahal Palace, ... applicants based on a variety of qualitative and quantitative ...
Breaking Medicine Technology:Automated Endoscope Reprocessor Market Trends in Western Europe 2Automated Endoscope Reprocessor Market Trends in Western Europe 3Global Freeze Drying / Lyophilization Equipment (Lab, Pilot, & Industrial) Market - Forecast to 2019 2Global Freeze Drying / Lyophilization Equipment (Lab, Pilot, & Industrial) Market - Forecast to 2019 3Recognising Impactful Healthcare Companies at VCCircle Healthcare Awards 2014 2Recognising Impactful Healthcare Companies at VCCircle Healthcare Awards 2014 3
...  SuccessEHS announces that its newest release will increase physician ... to previous releases.  The company has optimized features and ... and Practice Management software solution to make ... will focus on user efficiency and physician productivity ...
...  Snow tires? Check! Anti-freeze? Check! Window scraper? Check! Gloves? ... to prepare your skin for the effects of winter. ... skin that is rough, flaky, and downright unsightly. This ... it starts with AmLactin® Moisturizing Body Lotion. Wrap yourself ...
Cached Medicine Technology:Newest SuccessEHS Release to Increase Physician Software Usability 2Newest SuccessEHS Release to Increase Physician Software Usability 3Don't Let Your Skin Take a Backseat As You Prepare for Winter 2Don't Let Your Skin Take a Backseat As You Prepare for Winter 3
(Date:9/22/2014)... On Saturday, September 27, UHY LLP and UHY Cares ... is doing an amazing job helping kids and refurbishing school ... and friends will be spending the day at Academy of ... graphics, as well as clean the playground and surrounding park ... in May but due to weather conditions it was postponed ...
(Date:9/22/2014)... Sept. 22, 2014 (HealthDay News) -- Teens and young ... "intensive" behavioral counseling to help prevent risky sexual behaviors, ... Task Force. Every year, about 20 million new ... in the United States. About half involve people between ... force. Its new report, published Sept. 22 ...
(Date:9/22/2014)... HealthDay Reporter MONDAY, Sept. 22, ... newborn intensive care units (NICU) set up private rooms for ... finds. Researchers at one children,s hospital found that preemies ... when their NICU switched from the traditional "open-bay" layout to ... 22 in the journal Pediatrics , add to evidence ...
(Date:9/22/2014)... Malaysia today became a founding partner in the Global ... to promoting young talent in science, technology, engineering and ... New York Academy of Sciences (NYAS), Malaysian Prime Minister ... Monday Sept. 22. , With the goal of developing ... countries by 2020, the initiative will create a host ...
(Date:9/22/2014)... Recent two-generation approaches to reducing poverty that help ... from researchers, advocates, and foundations. By combining education ... move to jobs that offer a path out ... for children, these programs aim to improve the ... a new report from the National Center for ...
Breaking Medicine News(10 mins):Health News:Local CPA Firm Gears Up To Revamp Detroit Elementary School Playground 2Health News:Local CPA Firm Gears Up To Revamp Detroit Elementary School Playground 3Health News:Behavioral Counseling Urged for Teens, Young Adults at Risk for STDs 2Health News:Behavioral Counseling Urged for Teens, Young Adults at Risk for STDs 3Health News:Newborn ICUs With Private Family Rooms Benefit Preemies: Study 2Health News:Newborn ICUs With Private Family Rooms Benefit Preemies: Study 3Health News:Growing scientists: World's future jobs are rooted in STEM 2Health News:Growing scientists: World's future jobs are rooted in STEM 3Health News:A two-generation lens: Current state policies fail to support families with young children 2
... Updated Information Provided to Customers , LANDOVER, Md., Jan. ... to pull products containing peanut butter and peanut paste ... has traced the salmonella to a plant owned by ... recalled products from our shelves including:, ...
... The association between tobacco smoke and cancer deaths ... by a recent study from a UC Davis researcher, ... lives than previously estimated. , The epidemiological analysis, published ... more than 70 percent of the cancer death burden ...
... /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS) www.htdsmedical.com ... CEO. Terry is the current President and CEO of Shenzhen ... , a company targeted for a merger with HTDS. (See ... filings on Pink Sheets shortly. , Mr. Terry Yuan will ...
... to 50 million uninsuredsteeply rising insurance premiumsemployers cutting ... picture. In Disease, Diagnoses, and Dollars: Facing the ... Robert Kaplan takes America,s healthcare industry to task ... in it. , Provocative, timely, and comprehensively researched, ...
... MIAMI, Jan. 21 Financial services leader ING and the ... contest that,celebrates their success in the ING Run For Something ... The top three essays were submitted by ... Dade Middle School, 7th grade, -- Christian ...
... Favorite Body Parts: Our Faces are Fabulous; Tummies ... abs top the list of favorite and least favorite ... to a new survey conducted by American Laser Centers, ... U.S.Nearly a quarter of the men (24 percent) and ...
Cached Medicine News:Health News:Giant Food Responds to Recall of Peanut Based Products 2Health News:UC Davis study links smoking with most male cancer deaths 2Health News:Hard To Treat Diseases (HTDS) To Name New CEO and Directors 2Health News:ING and Fit Miami Foundation Name Winners of 'ING Run For Something Better' Student Essay Contest 2Health News:ING and Fit Miami Foundation Name Winners of 'ING Run For Something Better' Student Essay Contest 3Health News:ING and Fit Miami Foundation Name Winners of 'ING Run For Something Better' Student Essay Contest 4Health News:How Does Our Vanity Fare? 2
The iEMS Incubator/Shaker is a high performance microplate incubator and orbital shaker. Its superior temperature control and efficient orbital shaking reduce incubation times. -...
Minimal M9CA Broth...
Form: Cream-colored powder Moisture: 10% Ash: 6.5% Gel Strength (1.5%): 550 950 gm/cm 2 Gel pH (1.5%): 6.0 7.5 Gel Point (1.5%): 34 38C Melting Point (1.5%): 84 88C Application: Bacterial ...
...
Medicine Products: